Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in Sub-Saharan Africa

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Pantazis, Nikos ^a   Morrison, Charles ^b   Amornkul, Pauli N ^c   Lewden, Charlotte ^d,l   Salata, Robert A ^e   Minga, Albert ^f   Chipato, Tsungai ^g   Jaffe, Harold ^h   Lakhi, Shabir ⁱ   Karita, Etienne ^j   Porter, Kholoud ^k   Meyer, Laurence ^l   Touloumi, Giota ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b FAMILY HEALTH INTERNATIONAL   (United States)

^c International AIDS Vaccine Initiative   (United States)

^d UNIVERSITÉ DE BORDEAUX   (France)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

^f Programme PAC CI   (Côte d’Ivoire)

^g UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^h UNIVERSITY OF OXFORD   (United Kingdom)

ⁱ RZHRG   (Zambia)

^j Project San Francisco   (Rwanda)

^k MEDICAL RESEARCH COUNCIL   (United Kingdom)

^l INSERM   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AFRICA SOUTH OF THE SAHARA; AGE; ARTICLE; CAUCASIAN; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; EUROPE; FEMALE; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEGRO; PRACTICE GUIDELINE; RACE DIFFERENCE; SEROCONVERSION; SEX RATIO; SURVIVAL RATE; COMPARATIVE STUDY; IMMUNOLOGY; KAPLAN MEIER METHOD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; AFRICA SOUTH OF THE SAHARA; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DISEASE PROGRESSION; EUROPE; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; YOUNG ADULT;

EID: 84857807173     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032369     Document Type: Article

References (38)

1. Katzenstein DA, Hammer SM, Hughes MD, Gundacker H, Jackson JB, et al. (1996) The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. New England Journal of Medicine 335: 1091-1098.
2. Pantaleo G, Graziosi C, Fauci AS, (1993) The Immunopathogenesis of Human-Immunodeficiency-Virus Infection. New England Journal of Medicine 328: 327-335.
3. OBrien WA, Hartigan PM, Martin D, Esinhart J, Hill A, et al. (1996) Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. New England Journal of Medicine 334: 426-431.
4. Sterling TR, Vlahov D, Astemborski J, Hoover DR, Margolick JB, et al. (2001) Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. New England Journal of Medicine 344: 720-725.
5. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, et al. (1997) Plasma viral load and CD4(+) lymphocytes as prognostic markers of HIV-1 infection. Annals of Internal Medicine 126: 946-954.
6. Adolescents. PoAGfAa (2009) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 2010 Dec 6.
7. UNAIDS (2010) Report on the Global AIDS Epidemic. Available: http://www.unaids.org/globalreport/Global_report.htm. Accessed 2012 Feb 3.
8. Deuffic-Burban S, Losina E, Wang B, Gabillard D, Messou E, et al. (2007) Estimates of opportunistic infection incidence or death within specific CD4 strata in HIV-infected patients in Abidjan, Cote d'Ivoire: impact of alternative methods of CD4 count modelling. European Journal of Epidemiology 22: 737-744.
9. Jaffar S, Grant AD, Whitworth J, Smith PG, Whittle H, (2004) The natural history of HIV-1 and HIV-2 infections in adults in Africa: a literature review. Bulletin of the World Health Organization 82: 462-469.
10. Morgan D, Malamba SS, Maude GH, Okongo MJ, Wagner HU, et al. (1997) An HIV-1 natural history cohort and survival times in rural Uganda. AIDS 11: 633-640.
11. Mekonnen Y, Geskus RB, Hendriks JC, Messele T, Borghans J, et al. (2005) Low CD4 T cell counts before HIV-1 seroconversion do not affect disease progression in Ethiopian factory workers. J Infect Dis 192: 739-748.
12. Meyer LCM-L, Nagy Z, Venet A, Deveau C, Pacanovski J, et al. (2007) Low CD4 T cell counts in sub-Saharan African subjects enrolled at the time of HIV-1 primary infection in the French ANRS PRIMO cohort. Proceedings of the 4th IAS conference on HIV pathogenis, treatment and prevention. July 22-25, 2007 ed.
13. Keller M, Lu Y, Lalonde RG, Klein MB, (2009) Impact of HIV-1 viral subtype on CD4+ T-cell decline and clinical outcomes in antiretroviral naive patients receiving universal healthcare. AIDS 23: 731-737.
14. Lewden C, Thiebaut R, Boufassa F, Coulibaly A, Malateste K, et al. (2010) Comparison of Early CD4 T-Cell Count in HIV-1 Seroconverters in Cote d'Ivoire and France: The ANRS PRIMO-CI and SEROCO Cohorts. JAIDS-Journal of Acquired Immune Deficiency Syndromes 53: 260-265.
15. Porter K, Babiker A, Walker S, Darbyshire J, Gill N, et al. (2000) Effect of ignoring the time of HIV seroconversion in estimating changes in survival over calendar time in observational studies: results from CASCADE. AIDS 14: 1899-1906.
16. Anon (1992) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 41: 1-19.
17. Bhaskaran K, Hamouda O, Sannes M, Boufassa F, Johnson AM, et al. (2008) Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 300: 51-59.
18. Minga A, Danel C, Abo Y, Dohoun L, Bonard D, et al. (2007) Progression to WHO criteria for antiretroviral therapy in a 7-year cohort of adult HIV-1 seroconverters in Abidjan, Cote d'Ivoire. Bull World Health Organ 85: 116-123.
19. Price MA, Wallis CL, Lakhi S, Karita E, Kamali A, et al. (2011) Transmitted HIV Type 1 Drug Resistance Among Individuals with Recent HIV Infection in East and Southern Africa. AIDS Res Hum Retroviruses 27: 5-12.
20. Morrison CS, Richardson BA, Mmiro F, Chipato T, Celentano DD, et al. (2007) Hormonal contraception and the risk of HIV acquisition. AIDS 21: 85-95.
21. Morrison CS, Demers K, Kwok C, Bulime S, Rinaldi A, et al. (2010) Plasma and cervical viral loads among Ugandan and Zimbabwean women during acute and early HIV-1 infection. AIDS 24: 573-582.
22. Phillips AN, Lee CA, Elford J, Janossy G, Kernoff PBA, (1992) The Cumulative Risk of Aids as the Cd4 Lymphocyte Count Declines. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 5: 148-152.
23. Laird NM, Ware JH, (1982) Random-Effects Models for Longitudinal Data. Biometrics 38: 963-974.
24. Taylor JMG, Law N, (1998) Does the covariance structure matter in longitudinal modelling for the prediction of future CD4 counts? Statistics in Medicine 17: 2381-2394.
25. Laird NM, (1988) Missing data in longitudinal studies. Stat Med 7: 305-315.
26. Touloumi G, Pocock SJ, Babiker AG, Darbyshire JH, (1999) Estimation and comparison of rates of change in longitudinal studies with informative drop-outs. Statistics in Medicine 18: 1215-1233.
27. Pantazis N, Touloumi G, (2010) Analyzing longitudinal data in the presence of informative drop-out: The jmre1 command. Stata Journal 10: 226-251.
28. Urassa W, Bakari M, Sandstrom E, Swai A, Pallangyo K, et al. (2004) Rate of decline of absolute number and percentage of CD4 T lymphocytes among HIV-1-infected adults in Dar es Salaam, Tanzania. AIDS 18: 433-438.
29. Muller V, von Wyl V, Yerly S, Boni J, Klimkait T, et al. (2009) African descent is associated with slower CD4 cell count decline in treatment-naive patients of the Swiss HIV Cohort Study. AIDS 23: 1269-1276.
30. Katubulushi M, Zulu I, Yavwa F, Kelly P, (2005) Slow decline in CD4 cell count in a cohort of HIV-infected adults living in Lusaka, Zambia. AIDS 19: 102-103.
31. Tollerud DJ, Clark JW, Brown LM, Neuland CY, Pankiw-Trost LK, et al. (1989) The influence of age, race, and gender on peripheral blood mononuclear-cell subsets in healthy nonsmokers. J Clin Immunol 9: 214-222.
32. Troude P, Chaix ML, Tran L, Deveau C, Seng R, et al. (2009) No evidence of a change in HIV-1 virulence since 1996 in France. AIDS 23: 1261-1267.
33. Lovvorn AE, Patnaik P, Walker CJ, Kwok C, Van Der Pol B, et al. (2010) Variations in CD4 cell counts among HIV-uninfected and infected women in Uganda and Zimbabwe. Int J STD AIDS 21: 342-345.
34. Pisell TL, Hoffman IF, Jere CS, Ballard SB, Molyneux ME, et al. (2002) Immune activation and induction of HIV-1 replication within CD14 macrophages during acute Plasmodium falciparum malaria coinfection. AIDS 16: 1503-1509.
35. Crowe SM, Carlin JB, Stewart KI, Lucas CR, Hoy JF, (1991) Predictive Value of Lymphocyte-Cd4 Numbers for the Development of Opportunistic Infections and Malignancies in Hiv-Infected Persons. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 4: 770-776.
36. WHO (2011) Guidelines for intensified TB case-finding and INH preventive therapy for people living with HIV in resource-constrained settings. Available: http://www.who.int/hiv/pub/tb/9789241500708/en/index.html. Accessed 2012 Feb 3.
37. Schiffer V, Deveau C, Meyer L, Iraqui I, Nguyen-Wartel A, et al. (2004) Recent changes in the management of primary HIV-1 infection: results from the French PRIMO cohort. HIV Med 5: 326-333.
38. Lodi S, Phillips A, Touloumi G, Pantazis N, Bucher HC, et al. (2010) CD4 decline in seroconverter and seroprevalent individuals in the precombination of antiretroviral therapy era. AIDS 24: 2697-2704.